Geron Corporation GERN

Full chart Compare

Set alert

1.00 USD +0.01 (+0.68%)

At closeNov 10, 2026, 4:00 AM EST

1.00 0.00 0.00%

Pre-market · Nov 10, 4:00 AM ET

0.9739 Day range 1.00

0.84 52-week range 2.01

YTD: -24.51%
1 year: -14.09%

News

4 days ago defenseworld.net Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
4 days ago fool.com Geron: 3 Key Takeaways for Long-Term Investors RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.
5 days ago marketbeat.com Geron Q3 Earnings Call Highlights Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing,…
5 days ago seekingalpha.com Geron Corporation (GERN) Q3 2026 Earnings Call Transcript Geron Corporation (GERN) Q3 2026 Earnings Call Transcript
5 days ago zacks.com Geron (GERN) Reports Break-Even Earnings for Q3 Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.
5 days ago benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
5 days ago globenewswire.com Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people…
5 days ago benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
5 days ago globenewswire.com Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
6 days ago globenewswire.com Geron Corporation to Participate in the Stifel 2026 Healthcare Conference FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
1 week ago benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
1 week ago benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
1 week ago benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.